Recruiting

Study on Ceftriaxone Dosing for Patients with Severe Community-Acquired Pneumonia

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as severe community-acquired pneumonia, which is a serious lung infection that people can get outside of a hospital setting. The treatment being tested in this study is a medication called ceftriaxone, which is an antibiotic given as a solution for injection. The purpose of the study is to evaluate the benefits and safety of different dosing schedules of ceftriaxone in patients who are critically ill with this type of pneumonia.

Participants in the study will receive ceftriaxone either every 24 hours or every 12 hours, depending on their risk for a condition called augmented renal clearance (ARC). ARC is when the kidneys clear drugs from the body faster than usual, which can affect how well the medication works. The study will monitor various outcomes, such as the length of stay in the intensive care unit (ICU), survival rates, and the effectiveness of the treatment in clearing the infection.

The study will also look at other factors, such as the number of days patients are free from needing a ventilator, the presence of any side effects, and changes in certain blood markers that indicate infection. The trial aims to provide valuable information on how to best use ceftriaxone to treat severe community-acquired pneumonia in critically ill patients.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the trial
Participation begins with obtaining voluntary written informed consent. This can be done by the participant or their legally authorized representative. Consent must be obtained before or within 72 hours after oral consent prior to any screening procedures.
Participants must use highly effective methods of birth control during the trial. This includes options like implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), true sexual abstinence, or having a vasectomized partner.
Participants must be 18 years or older and have a confirmed diagnosis of severe community-acquired pneumonia (sCAP) as defined by current guidelines.
Step 2
Treatment administration
The treatment involves the administration of ceftriaxone, a medication used to treat bacterial infections. It is given through an intravenous infusion.
The dosage of ceftriaxone is 2 grams. The frequency of administration is either every 24 hours (q24h) or every 12 hours (q12h), depending on the patient's risk for developing augmented renal clearance (ARC).
The treatment is specifically for patients with severe community-acquired pneumonia who are admitted to an intensive care unit (ICU).
Step 3
Monitoring and evaluation
The primary endpoint of the trial is the length of stay in the ICU.
Secondary endpoints include changes in the Sequential Organ Failure Assessment (SOFA) score, ICU mortality, 28-day mortality, hospital length of stay, and the number of days alive and free from the ICU and ventilator at day 28.
Other evaluations include clinical cure and microbial eradication at day 14, emergence of resistance, pharmacokinetic/pharmacodynamic (PK/PD) target attainment, safety assessment, and measurement of procalcitonin and C-reactive protein concentrations.
Step 4
Trial duration
The estimated recruitment start date for the trial is January 1, 2024.
The trial is expected to end by January 1, 2026.

Who can join the trial?

6 criteria

The participant or their legally authorized representative must provide written informed consent before or within 72 hours after giving oral consent for any screening procedures. This means they agree to join the study after understanding what it involves.
Participants must use highly effective birth control methods. These are methods that have a very low chance of failing, like implants, injections, certain birth control pills, some intrauterine devices (IUDs), not having sex, or having a partner who has had a vasectomy.
Participants must be 18 years or older at the start of the study.
Participants must have a confirmed diagnosis of severe Community-Acquired Pneumonia (sCAP), according to the guidelines from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS).
Participants must have started treatment with ceftriaxone for their severe Community-Acquired Pneumonia (sCAP). Ceftriaxone is a type of antibiotic used to treat infections.
Participants must be planned to be admitted to an Intensive Care Unit (ICU). This is a special hospital ward for patients who need close monitoring and support.

Who cannot join the trial?

6 criteria

Patients who are not critically ill with Severe Community-Acquired Pneumonia cannot participate. This means the study is only for those who are very sick with a specific type of lung infection.
Patients who are not at risk for developing ARC (Augmented Renal Clearance) cannot participate. ARC is a condition where the kidneys clear drugs from the body faster than normal.
Patients who do not fall within the specified age ranges cannot participate. The study is for certain age groups only.
Patients who are not part of the specified clinical trial groups cannot participate. This means the study is for specific groups of people.
Patients who are not male or female cannot participate. The study includes both men and women.
Patients who are not considered part of a vulnerable population cannot participate. Vulnerable populations may include groups like children, elderly, or those with certain health conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Algemeen Ziekenhuis Delta
Roeselare, Belgium
Verified
Az St-Jan Brugge-Oostende A.V.
Brugge, Belgium
Responsive
Katholieke Universiteit te Leuven
Leuven, Belgium

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ceftriaxone is an antibiotic used to treat severe community-acquired pneumonia. In this trial, it is being studied to see if adjusting the frequency of doses based on kidney function can improve treatment outcomes for critically ill patients. The study compares giving the medication every 24 hours versus every 12 hours to determine which schedule is more effective and safe.

Ceftriaxone

What is already known about the treatment

Ceftriaxone – Ceftriaxone is administered intravenously or intramuscularly, typically in a hospital setting. It is currently being studied in clinical trials for its effectiveness in treating severe community-acquired pneumonia, particularly in critically ill patients. The medication is primarily used to treat bacterial infections by inhibiting the synthesis of the bacterial cell wall, leading to cell death. Ceftriaxone is classified as a third-generation cephalosporin antibiotic, known for its broad-spectrum activity against various bacteria.

Investigated diseases

Severe Community-Acquired Pneumonia – This is a serious lung infection acquired outside of a hospital setting. It typically begins with symptoms like cough, fever, and difficulty breathing. As the disease progresses, it can lead to severe respiratory distress and may require hospitalization. The infection can spread to the bloodstream, causing further complications. In severe cases, patients may need intensive care support, including mechanical ventilation. The condition is more common in individuals with weakened immune systems or underlying health issues.